Jivi® is the EHL rFVIII that offers effective bleed protection with a unique step-wise prophylaxis dosing regimen1,2

Study Design Chart

Treatment success in the every 7 day arm was not established1

  • Total ABR in all patients on every 7 day dosing arm (n=43); Median (Q1;Q3) ABR for total bleeds of 3.9 (0.0;6.5) and a Mean (±SD) of 6.43 (±10.04)3,4
  • Total ABR in patients who completed every 7 day dosing treatment (n=32); Median (Q1;Q3) ABR of 1.0 (0.0;4.3) and a Mean (±SD) of 2.67 (±3.82)3,4
  • Spontaneous ABR in all patients on every 7 day arm (n=43); Median (Q1;Q3) of 1.9 (0.0,6.3) and Mean (±SD) of 5.42 (±9.79)4
  • Spontaneous ABR in patients who completed every 7 day dosing treatment (n=32); Median (Q1;Q3) of 0.0 (0.0;2.1) and Mean (±SD) of 1.65 (±2.89)4
  • Patients with 0 or 1 spontaneous bleed (defined as a joint or muscle bleed and no identified trauma) during weeks 1-10 of the main study.3
  • Patients with 2 or more spontaneous bleeds (defined as joint or muscle bleeds and no identified trauma) during weeks 1-10 of the main study.3
  • n=9/13 of these patients were on prior prophylaxis and had a mean number total ABR of 17.4 before entering the main study.1
  • ABR, annualized bleed rate; EHL, extended half-life; Q, quartile; rFVIII, recombinant Factor VIII; SD, standard deviation.